Shared on04 Aug 25Fair value Decreased 18%
The consensus analyst price target for Avantor has been significantly reduced, primarily due to notable declines in both revenue growth forecasts and net profit margin expectations, resulting in a new fair value estimate of $14.12. What's in the News Emmanuel Ligner appointed President and CEO, succeeding Michael Stubblefield; Ligner brings extensive life sciences leadership experience from GE Life Sciences, Cytiva, and Cerba HealthCare.
Shared on30 Apr 25Fair value Decreased 23%
AnalystConsensusTarget has increased revenue growth from 2.5% to 3.0% and decreased profit margin from 9.6% to 8.0%.
Shared on23 Apr 25Fair value Decreased 0.90%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Increased 31%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 1.96%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.65%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 43%
AnalystConsensusTarget has decreased revenue growth from 2.9% to 2.4%.